Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aprea Therapeutics Inc (NQ: APRE )

3.470 +0.070 (+2.06%)
Streaming Delayed Price Updated: 12:21 PM EDT, May 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 10,220
Open 3.400
Bid (Size) 3.380 (3)
Ask (Size) 3.500 (2)
Prev. Close 3.400
Today's Range 3.330 - 3.552
52wk Range 3.330 - 25.80
Shares Outstanding 3,731,571
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Aprea Therapeutics to Present at BIO International Convention
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Reports First Quarter 2023 Financial Results and Provides Update on Business Operations
From Aprea Therapeutics
Via GlobeNewswire

Performance

YTD
-53.73%
-53.73%
1 Month
-9.75%
-9.75%
3 Month
-31.42%
-31.42%
6 Month
-53.16%
-53.16%
1 Year
-79.28%
-79.28%

More News

Read More
Aprea Therapeutics Appoints Gabriela Gruia, M.D. to Board of Directors
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Inc. (NASDAQ: APRE) Making Surprising Moves in Thursday Session
Via Investor Brand Network
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
Via Benzinga
Aprea Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Update on Business Operations
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Announces Presentation of Preclinical Data on Pipeline Programs at the AACR 2023 Annual Meeting
From Aprea Therapeutics
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For March 10, 2023
Via Benzinga
Aprea Therapeutics to Present at Oppenheimer’s 33rd Annual Healthcare Conference
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Announces Closing of $5.5 Million Underwritten Public Offering of Common Stock
From Aprea Therapeutics
Via GlobeNewswire
Why Aprea Therapeutics Shares Hit A New 52-Week Low Today
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Aprea Therapeutics Announces Pricing of $5.5 Million Underwritten Public Offering of Common Stock
From Aprea Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Aprea Therapeutics Announces Proposed Public Offering of Common Stock
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Announces Phase II SBIR Award from the National Cancer Institute (NCI)
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Announces One-for-Twenty Reverse Stock Split
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Appoints John Hamill as Chief Financial Officer
From Aprea Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Aprea Therapeutics to Participate in 6th Annual DNA Damage and Response (DDR) Inhibitors Summit
From Aprea Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Aprea Therapeutics Announces Dosing of First Patient in Phase 1/2a Clinical Trial of Oral ATR Inhibitor ATRN-119 for the Treatment of Advanced Solid Tumors
From Aprea Therapeutics
Via GlobeNewswire
Why ABVC BioPharma Shares Are Trading Higher By 129%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.